Lok A, Mocquard J, Bourcier J, Redelsperger L, Bonnet A, Chauvin C, Thomaré P, Mahé B, Touzeau C, Moreau P. Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma. Haematologica [Internet]. 2014Mar.5 [cited 2026Nov.13];99(3):e33-e34. Available from: https://haematologica.org/article/view/6981